AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY23 results · Oct–Dec 2022
AstraZeneca Pharma India reported revenue from operations of ₹249.81 crore (up 24.6% from Q3 FY22) and net profit of ₹29.30 crore (up 156.6% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a standalone basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 249.81 | 200.53 | +24.6% | 236.13 | +5.8% |
| Other income | 7.20 | 5.33 | +35.0% | 6.79 | +5.9% |
| Total income | 257.00 | 205.86 | +24.8% | 242.92 | +5.8% |
| Profit before tax | 39.46 | 16.26 | +142.6% | 44.07 | −10.5% |
| Net profit for the period | 29.30 | 11.42 | +156.6% | 32.56 | −10.0% |
| EPS, basic (₹) | 11.72 | 4.57 | +156.6% | 13.03 | −10.0% |
| Net margin (%) | 11.7 | 5.7 | 13.8 |
Standalone
- Filed with BSE
- 11 Feb 2023, 11:51 IST
- Board meeting
- 10 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE